Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2016
18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Joint EANM-SNMMI guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2024Guideline
- Prognostic value ofBreast cancer research : BCR · 2020Pooled it
- Habitat-aware radiomics and adaptive 2.5D deep learning predict treatment response and long-term survival in ESCC patients undergoing neoadjuvant chemoimmunotherapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Early tumour size changes from neoadjuvant chemotherapy as a predictor of pathologic response in breast cancer.PloS one · 2026Article
- Respective contribution of baseline clinical data, tumour metabolism and tumour blood-flow in predicting pCR after neoadjuvant chemotherapy in HER2 and Triple Negative breast cancer.EJNMMI research · 2024Article
- Changes in the tumor oxygenation but not in the tumor volume and tumor vascularization reflect early response of breast cancer to neoadjuvant chemotherapy.Breast cancer research : BCR · 2023Article
- Artificial Intelligence and Precision Medicine: A New Frontier for the Treatment of Brain Tumors.Life (Basel, Switzerland) · 2022Review
- Principles of Tracer Kinetic Analysis in Oncology, Part II: Examples and Future Directions.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Breast Tumor Characterization Using [Cancers · 2021Article
- Article
- Biological correlates of tumor perfusion and its heterogeneity in newly diagnosed breast cancer using dynamic first-passEuropean journal of nuclear medicine and molecular imaging · 2020Article
- A Novel Model Incorporating Tumor Stiffness, Blood Flow Characteristics, and Ki-67 Expression to Predict Responses After Neoadjuvant Chemotherapy in Breast Cancer.Frontiers in oncology · 2020Article
- Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.OncoTargets and therapy · 2020Review
- PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [Molecular imaging and biology · 2019Article
- Article
- Compact ultrasound-guided diffuse optical tomography system for breast cancer imaging.Journal of biomedical optics · 2018Article
- Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.Breast cancer research : BCR · 2018Article
- Getting the Most out of 18F-FDG PET Scans: The Predictive Value of 18F-FDG PET-Derived Blood Flow Estimates for Breast Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Article
- Prognostic factors in breast cancer patients evaluated by positron-emission tomography/computed tomography before neoadjuvant chemotherapy.World journal of nuclear medicineArticle
Corrections and comments
- Commented on by
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have suggested that early changes in blood flow (BF) in response to neoadjuvant chemotherapy and evaluated with
methodsForty-six consecutive women with triple-negative breast cancer and an indication for neoadjuvant chemotherapy were prospectively included. Women benefited from a baseline
resultsMedian baseline tumor BF was 21 mL/min/100 g (range, 6-46 mL/min/100 g) and did not significantly differ according to tumor size, Scarf-Bloom-Richardson grade, or Ki-67 expression. Median tumor ∆BF was -30%, with highly scattered values (range, -93% to +118%). A weak correlation was observed between ΔBF and ∆SUV
conclusionThis study suggests the clinical usefulness of an early user- and patient-friendly 2-min dynamic acquisition to monitor breast tumor ΔBF to neoadjuvant chemotherapy using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.